Tisdale Risk Score for QT Prolongation
Predicts risk of drug-induced QT prolongation in hospitalised patients.
Score interpretation
Tisdale 0–6: QTc prolongation (> 500 ms or rise > 60 ms) in 15% of the validation group.
→ Standard ECG monitoring. Review QT-prolonging drug use.
Tisdale 7–10: QTc prolongation in 37% of the validation group.
→ Serial ECG monitoring. Correct electrolytes. Review and minimise QT-prolonging drugs.
Tisdale ≥ 11: QTc prolongation in 73% of the validation group.
→ Frequent ECG monitoring. Avoid unnecessary QT-prolonging agents. Correct electrolytes. Pharmacy review.
Interpretation bands for the Tisdale QT. Apply clinical judgement and local guidance.
References
- Tisdale JE et al. Development and Validation of a Risk Score to Predict QT-Interval Prolongation in Hospitalized Patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487.
Related
Curated clinical cross-links plus same-class fallbacks.
- Phenylephrine · Alpha-1 Adrenergic Agonist (Pure Vasoconstrictor)
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Carbimazole · Antithyroid Drug
- Diclofenac · Non-Steroidal Anti-Inflammatory Drug (NSAID)
- Zopiclone · Non-Benzodiazepine Hypnotic (Z-drug)
- Diclofenac · NSAID (Non-Steroidal Anti-Inflammatory Drug)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.